Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Addex Therapeutics (ADXN) over the last 4 years, with Q2 2025 value amounting to -$118.4 billion.

  • Addex Therapeutics' Cash from Financing Activities rose 3495.05% to -$118.4 billion in Q2 2025 from the same period last year, while for Jun 2025 it was -$8.0 billion, marking a year-over-year increase of 9987.08%. This contributed to the annual value of $119260.5 for FY2024, which is 9796.55% down from last year.
  • According to the latest figures from Q2 2025, Addex Therapeutics' Cash from Financing Activities is -$118.4 billion, which was up 3495.05% from $109.0 billion recorded in Q1 2025.
  • Addex Therapeutics' Cash from Financing Activities' 5-year high stood at $6130.2 billion during Q2 2023, with a 5-year trough of -$6000.8 billion in Q4 2023.
  • Its 4-year average for Cash from Financing Activities is -$6.1 billion, with a median of -$176047.7 in 2022.
  • Within the past 5 years, the most significant YoY rise in Addex Therapeutics' Cash from Financing Activities was 346783316935.01% (2023), while the steepest drop was 342275858073.99% (2023).
  • Quarter analysis of 4 years shows Addex Therapeutics' Cash from Financing Activities stood at -$175321.9 in 2022, then crashed by 3422758580.74% to -$6000.8 billion in 2023, then surged by 97.97% to -$121.7 billion in 2024, then grew by 2.77% to -$118.4 billion in 2025.
  • Its last three reported values are -$118.4 billion in Q2 2025, $109.0 billion for Q1 2025, and -$121.7 billion during Q4 2024.